Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Phase 2 Double-Blind Study of JTZ-951 (enarodustat) in Anemic CKD Patients on Hemodialysis
jRCT2080222839Phase 2Completed
- Sponsor
- Japan Tobacco
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enarodustat in anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Japan Tobacco. Primary endpoint: Hemoglobin level increase rate and dose–response. Started May 2015; status: completed.
02
Drugs
enarodustat
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080222839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222839.